AIM ImmunoTech announces preliminary results of rights offering

AIM ImmunoTech (AIM) announced the preliminary results of its previously announced rights offering which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8M. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions. Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock, and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock. The Company anticipates the closing of the Rights Offering will occur on or about March 6, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.